| Primary |
| Product Used For Unknown Indication |
19.0% |
| Non-hodgkin's Lymphoma |
17.5% |
| Lymphoma |
10.8% |
| B-cell Lymphoma |
8.1% |
| Breast Cancer |
8.0% |
| Ewing's Sarcoma |
6.9% |
| Diffuse Large B-cell Lymphoma |
6.2% |
| Chronic Lymphocytic Leukaemia |
2.6% |
| Burkitt's Leukaemia |
2.4% |
| Burkitt's Lymphoma |
2.3% |
| Prophylaxis |
2.3% |
| Plasma Cell Myeloma |
2.2% |
| Acute Lymphocytic Leukaemia |
2.1% |
| Anti-neutrophil Cytoplasmic Antibody Positive Vasculitis |
2.1% |
| Mantle Cell Lymphoma |
1.8% |
| Drug Use For Unknown Indication |
1.7% |
| Acute Myeloid Leukaemia |
1.1% |
| Hematological Malignancy |
1.0% |
| Germ Cell Cancer |
0.9% |
| Peripheral T-cell Lymphoma Unspecified |
0.9% |
|
| No Adverse Event |
25.7% |
| Death |
25.2% |
| Pneumonitis |
12.1% |
| Myelodysplastic Syndrome |
7.2% |
| Pneumonia |
3.7% |
| Neoplasm |
3.0% |
| Acute Myeloid Leukaemia |
2.7% |
| Skin Cancer |
2.5% |
| Neutropenia |
2.2% |
| Transplant Rejection |
2.2% |
| Toxicity To Various Agents |
2.0% |
| Disease Progression |
1.7% |
| Bacteraemia |
1.5% |
| Pulmonary Embolism |
1.5% |
| Sepsis |
1.5% |
| Deep Vein Thrombosis |
1.2% |
| Febrile Neutropenia |
1.2% |
| Breast Cancer |
1.0% |
| Leukaemia Recurrent |
1.0% |
| Thrombocytopenia |
1.0% |
|
| Secondary |
| Non-hodgkin's Lymphoma |
27.3% |
| Product Used For Unknown Indication |
16.4% |
| Sarcoma |
15.4% |
| B-cell Lymphoma |
13.3% |
| Burkitt's Leukaemia |
4.0% |
| Burkitt's Lymphoma |
3.9% |
| Prophylaxis |
3.5% |
| Hematological Malignancy |
3.2% |
| Immunosuppression |
2.2% |
| Acute Lymphocytic Leukaemia |
2.0% |
| Drug Use For Unknown Indication |
1.3% |
| Opsoclonus Myoclonus |
1.2% |
| Her-2 Positive Breast Cancer |
1.2% |
| Breast Cancer |
0.9% |
| Hyper Igm Syndrome |
0.9% |
| Diffuse Large B-cell Lymphoma |
0.8% |
| Allergy Test |
0.8% |
| Neoplasm Malignant |
0.8% |
| Medulloblastoma |
0.5% |
| Metastases To Lymph Nodes |
0.4% |
|
| Death |
44.6% |
| Febrile Neutropenia |
15.5% |
| Myelodysplastic Syndrome |
5.7% |
| Bacteraemia |
5.2% |
| Skin Cancer |
5.2% |
| Neoplasm |
4.1% |
| Pyrexia |
3.1% |
| Pneumonia |
2.6% |
| Infection |
2.1% |
| Leukaemia Recurrent |
2.1% |
| Lung Infection |
1.6% |
| Renal Failure Acute |
1.6% |
| Traumatic Lung Injury |
1.6% |
| Embolism Venous |
1.0% |
| Haematological Malignancy |
1.0% |
| Pulmonary Toxicity |
1.0% |
| Calculus Ureteric |
0.5% |
| Cardiomyopathy |
0.5% |
| Colitis |
0.5% |
| Colorectal Cancer |
0.5% |
|
| Concomitant |
| Breast Cancer |
50.0% |
| Product Used For Unknown Indication |
35.7% |
| Hypertension |
14.3% |
|
| Disease Progression |
100.0% |
|
